44 related articles for article (PubMed ID: 35962819)
1. Venetoclax Clinical Pharmacokinetics After Administration of Crushed, Ground or Whole Tablets.
Alaei S; Wang Y; Liu Y; Schiele J; Deng R; Shiller D; Marroum P; Menon R; Salem AH
Clin Ther; 2024 May; ():. PubMed ID: 38782609
[TBL] [Abstract][Full Text] [Related]
2. Overexposure to venetoclax is associated with prolonged-duration of neutropenia during venetoclax and azacitidine therapy in Japanese patients with acute myeloid leukemia.
Kobayashi T; Sato H; Miura M; Fukushi Y; Kuroki W; Ito F; Teshima K; Watanabe A; Fujishima N; Kobayashi I; Kameoka Y; Takahashi N
Cancer Chemother Pharmacol; 2024 May; ():. PubMed ID: 38782790
[TBL] [Abstract][Full Text] [Related]
3. Relative Bioavailability of Cenobamate Administered as a Crushed Tablet, Either Orally or via Nasogastric Tube, versus an Intact Whole Tablet.
Vashi V; Laramy J; Kamin M; Ferrari L; Hand A
J Clin Pharmacol; 2024 Apr; ():. PubMed ID: 38683027
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of Edaravone Oral Suspension in Patients With Amyotrophic Lateral Sclerosis.
Shimizu H; Nishimura Y; Shiide Y; Akimoto M; Yashiro M; Ueda M; Hirai M; Yoshino H; Mizutani T; Kanai K; Kano O; Kimura H; Sekino H; Ito K
Clin Ther; 2023 Dec; 45(12):1251-1258. PubMed ID: 37953075
[TBL] [Abstract][Full Text] [Related]
5. Crushing the Contents of Valbenazine Capsules for Potential Addition to Soft Foods or Administration via Gastrostomy Tube.
Sajatovic M; Patel A; Hebert M; Mar A; Moore R; Bristow A; Farahmand K; Siegert S
Clin Ther; 2023 Dec; 45(12):1222-1227. PubMed ID: 37953076
[TBL] [Abstract][Full Text] [Related]
6. Venetoclax in association with decitabine as effective bridge to transplant in a case of relapsed early T-cell lymphoblastic leukemia.
Zappone E; Cencini E; Defina M; Sicuranza A; Gozzetti A; Ciofini S; Raspadori D; Mecacci B; Bocchia M
Clin Case Rep; 2020 Oct; 8(10):2000-2002. PubMed ID: 33088538
[TBL] [Abstract][Full Text] [Related]
7. Crushed Posaconazole Delayed-Release Tablets Via Enteral Feeding Tubes: A Cautionary Tale.
Kane N; Rikard R; McCrory K; Marx A
Ann Pharmacother; 2024 Apr; ():10600280241249705. PubMed ID: 38686669
[No Abstract] [Full Text] [Related]
8. Orogastric administration of crushed darunavir tablets for a critically ill patient.
Kim CH; Muzevich KM; Fulco PP
Can J Hosp Pharm; 2014 Jan; 67(1):39-42. PubMed ID: 24634526
[No Abstract] [Full Text] [Related]
9. Impact of tablet crushing on the dissolution of venetoclax.
Yasu T; Hikita E; Gando Y; Odate M; Inoue M; Shirota M
Ann Hematol; 2023 Jan; 102(1):219-220. PubMed ID: 36333488
[No Abstract] [Full Text] [Related]
10. An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine as therapy for acute myeloid leukemia.
Othman TA; Tenold ME; Moskoff BN; Azenkot T; Jonas BA
Expert Rev Hematol; 2021 May; 14(5):407-417. PubMed ID: 34076549
[TBL] [Abstract][Full Text] [Related]
11. Can we selectively target AML stem cells?
Jordan CT
Best Pract Res Clin Haematol; 2019 Dec; 32(4):101100. PubMed ID: 31779978
[TBL] [Abstract][Full Text] [Related]
12. Safe administration and pharmacokinetic monitoring of crushed venetoclax tablets with posaconazole and clarithromycin via percutaneous endoscopic gastrostomy tube in a patient with acute myeloid leukemia.
Sato H; Kobayashi T; Fujita N; Yamashita T; Kitadate A; Yoshioka T; Nara M; Kameoka Y; Miura M; Takahashi N
Cancer Chemother Pharmacol; 2022 Sep; 90(3):279-284. PubMed ID: 35962819
[TBL] [Abstract][Full Text] [Related]
13. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
[TBL] [Abstract][Full Text] [Related]
14. Management of Venetoclax-Posaconazole Interaction in Acute Myeloid Leukemia Patients: Evaluation of Dose Adjustments.
Agarwal SK; DiNardo CD; Potluri J; Dunbar M; Kantarjian HM; Humerickhouse RA; Wong SL; Menon RM; Konopleva MY; Salem AH
Clin Ther; 2017 Feb; 39(2):359-367. PubMed ID: 28161120
[TBL] [Abstract][Full Text] [Related]
15. Dose adjustment of venetoclax when co-administered with posaconazole: clinical drug-drug interaction predictions using a PBPK approach.
Bhatnagar S; Mukherjee D; Salem AH; Miles D; Menon RM; Gibbs JP
Cancer Chemother Pharmacol; 2021 Apr; 87(4):465-474. PubMed ID: 33398386
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
